KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2016 - 2025)

Alnylam Pharmaceuticals' Total Current Liabilities history spans 17 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 23.61% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 23.61%, while the annual FY2025 figure was $1.5 billion, 23.61% up from the prior year.
  • Total Current Liabilities reached $1.5 billion in Q4 2025 per ALNY's latest filing, down from $1.6 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.6 billion in Q3 2025 to a low of $494.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $917.1 million, with a median of $865.2 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 46.06% in 2021, then grew 10.38% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $695.7 million in 2021, then rose by 10.38% to $767.9 million in 2022, then grew by 26.03% to $967.8 million in 2023, then increased by 22.58% to $1.2 billion in 2024, then grew by 23.61% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Total Current Liabilities are $1.5 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.3 billion (Q2 2025).